Lip GYH, et al. - This ancillary analysis compared edoxaban to enoxaparin–warfarin in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation in relation to stroke and bleeding risk profiles. In addition, researchers assessed the relation of patients' risk profiles to the time needed to achieve therapeutic range of anticoagulation, as well as to the quality of anticoagulation control in the warfarin arm. As per observations, edoxaban had numerically lower primary efficacy endpoint events and indicated a trend for higher odds ratios (ORs) with HAS-BLED score ≥3 compared with enoxaparin–warfarin in patients at high stroke risk. While bleeding risk was inversely correlated with quality of anticoagulation control, time to therapeutic range was shorter with higher CHA₂DS₂-VASc score.